Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502888 · ClinicalTrials.gov registry record · Phase 1
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
A Phase 1 study, sponsored by Shattuck Labs.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04502888: Clinical Trial Phase 1 study, sponsored by Shattuck Labs.
NCT04502888 is a Phase 1 study that was terminated before completion, run by Shattuck Labs. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04502888, a Phase 1 study, was terminated before completion, sponsored by Shattuck Labs.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell carcinoma of the head and neck (SCCHN).
Primary Outcome
Number of participants with treatment-emergent adverse events
Interventions
- DRUG Drug: SL-172154
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2022-04-08 |
| Phase | Phase 1 |
Why NCT04502888 stopped before completion
NCT04502888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Drug: SL-172154 is the first listed.
NCT04502888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04502888 about?
NCT04502888 is a clinical study titled "Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin". This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell carcinoma of the head and neck...
What is the current status of trial NCT04502888?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-09-17. Estimated completion is 2022-04-08.
What interventions are being tested in trial NCT04502888?
The interventions under investigation include: Drug: SL-172154 (DRUG).
Who is sponsoring clinical trial NCT04502888?
This trial is sponsored by Shattuck Labs, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04502888's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI